Executive Management

Dana Pizzuti serves as Chief Medical and Development Officer and joined Crinetics as Chief Officer in 2022. Dana is a board-certified physician with more than 30 years of pharmaceutical industry experience in clinical development, pharmacovigilance, and medical and regulatory affairs. 

Prior to Crinetics, Dana served as Senior Vice President, development operations and Chief Medical Officer at Ascendis Pharma, where she rebuilt the U.S. regulatory affairs unit into a streamlined global organization. At Ascendis, she led the company’s successful U.S. and European marketing applications for lonapegsomatropin, a combination drug-device product for children with growth hormone deficiency. Earlier in her career, Dana established the regulatory affairs function at Rigel Pharmaceuticals, where she directed the team responsible for the company’s first new drug application approval. She also previously led the global regulatory affairs unit at Gilead Sciences, managing over 500 people across 33 countries, leading to marketing authorizations for 15 new drugs in global markets. 

Dana holds a bachelor’s degree (cum laude) in biology from Yale University, and received her doctor of medicine degree from the NYU School of Medicine. She completed her medical internship and residency at NYU-Bellevue Hospital Center in New York City and a fellowship in infectious disease at Albert Einstein-Montefiore Medical Center.